×
About 14,420 results

ALLMedicine™ Amyloidosis Center

Research & Reviews  4,924 results

The flutemetamol analogue cyano-flutemetamol detects myocardial AL and ATTR amyloid dep...
https://doi.org/10.1080/13506129.2022.2141623
Amyloid : the International Journal of Experimental and C... Abrahamson EE, Padera RF et. al.

Nov 23rd, 2022 - [18F]flutemetamol is a PET radioligand used to image brain amyloid, but its detection of myocardial amyloid is not well-characterized. This histological study characterized binding of fluorescently labeled flutemetamol (cyano-flutemetamol) to amyl...

Validation of an administrative coding algorithm for the identification of individuals ...
https://doi.org/10.1080/10428194.2022.2136967
Leukemia & Lymphoma; Jimenez-Zepeda VH, Reece D et. al.

Nov 22nd, 2022 - Validation of an administrative coding algorithm for the identification of individuals with amyloid light chain amyloidosis using administrative data.|2022|Jimenez-Zepeda VH,Reece D,Rigo R,Gogna P,Kong S,|

Systemic light chain amyloidosis myopathy responsive to daratumumab monotherapy.
https://doi.org/10.1111/ene.15640
European Journal of Neurology; Chitimus DM, Berling E et. al.

Nov 21st, 2022 - Amyloid myopathy is a rare and severe manifestation of systemic light chain (AL) amyloidosis. Early diagnosis and staging are mandatory for optimal therapy, given the rapid progression of muscle weakness. Despite the efficacity of bortezomib-based...

Recent Developments in the Evaluation and Management of Cardiorenal Syndrome: A Compreh...
https://doi.org/10.1016/j.cpcardiol.2022.101509
Current Problems in Cardiology; Kim JA, Wu L et. al.

Nov 20th, 2022 - Cardiorenal syndrome (CRS) is increasingly recognized diagnostic entity associated with high morbidity and mortality among acutely ill heart failure (HF) patients with acute and/ or chronic kidney diseases (CKD). While traditionally viewed as a st...

A multidisciplinary case report of multiple myeloma with renal and cardiac involvement:...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9673363
BMC Nephrology; Innocenti S, Bacchi B et. al.

Nov 19th, 2022 - Multiple myeloma (MM) is a malignant neoplasm associated with kidney involvement in nearly half of the patients. Cast nephropathy, monoclonal immunoglobulin deposition disease (MIDD), and light chain (AL) amyloidosis are the most common monoclonal...

see more →

Guidelines  10 results

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodalit...
https://doi.org/10.1161/HCI.0000000000000029
Circulation. Cardiovascular Imaging; Dorbala S, Ando Y et. al.

Jul 2nd, 2021 - ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging.|2021|Dorbala S,Ando Y,Bokhari S,Dispenzieri A,Falk RH,|diagnost...

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodalit...
https://doi.org/10.1161/HCI.0000000000000030
Circulation. Cardiovascular Imaging; Dorbala S, Ando Y et. al.

Jul 2nd, 2021 - ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging in Cardiac Amyloidosis: Part 2 of 2-Diagnostic Criteria and Appropriate Utilization.|2021|Dorbala S,Ando Y,Bokhari S,Dispenzieri A,Falk RH,|diagnostic...

JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.
https://doi.org/10.1253/circj.CJ-20-0110
Circulation Journal : Official Journal of the Japanese Ci... Kitaoka H, Izumi C et. al.

Aug 25th, 2020 - JCS 2020 Guideline on Diagnosis and Treatment of Cardiac Amyloidosis.|2020|Kitaoka H,Izumi C,Izumiya Y,Inomata T,Ueda M,|classification,diagnosis,drug therapy,epidemiology,therapeutic use,classification,diagnosis,drug therapy,epidemiology,epidemio...

Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement ...
https://doi.org/10.1016/j.cjca.2019.12.025
The Canadian Journal of Cardiology; Chih S, McDonald M et. al.

Mar 9th, 2020 - Significant practice-changing developments have occurred in the care of heart transplantation candidates and recipients over the past decade. This Canadian Cardiovascular Society/Canadian Cardiac Transplant Network Position Statement provides evid...

Canadian Cardiovascular Society/Canadian Heart Failure Society Joint Position Statement...
https://doi.org/10.1016/j.cjca.2019.12.034
The Canadian Journal of Cardiology; Fine NM, Davis MK et. al.

Mar 9th, 2020 - Cardiac amyloidosis is an under-recognized and potentially fatal cause of heart failure and other cardiovascular manifestations. It is caused by deposition of misfolded precursor proteins as fibrillary amyloid deposits in cardiac tissues. The two ...

see more →

Drugs  12 results see all →

Clinicaltrials.gov  357 results

Characterization of Diseases With Salivary Gland Involvement
https://clinicaltrials.gov/ct2/show/NCT02327884

Oct 14th, 2022 - This protocol is intended to allow disease-specific investigations in subjects with presentations of diseases with salivary gland involvement and will enable the collection of data, biological fluids and tissue samples from those subjects, their f...

Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
https://clinicaltrials.gov/ct2/show/NCT05374564

Oct 14th, 2022 - The goal of this project is to perform a proof-of-concept study to compare the ability of quantitative parametric cardiac 18F-flutemetamol positron emission tomography (PET) to assess baseline and change in disease burden after six months of thera...

A Non-interventional Cohort Safety Study of Patients With hATTR-PN
https://clinicaltrials.gov/ct2/show/NCT04850105

Oct 13th, 2022 - Study Rationale: hATTR-PN is an inherited, progressive, fatal disease caused by misfolded transthyretin (TTR) proteins that accumulate as amyloid fibrils predominantly in the peripheral nerves, heart, gastrointestinal tract, and other organs. hATT...

Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
https://clinicaltrials.gov/ct2/show/NCT05577819

Oct 13th, 2022 - Patients 65-years and older with HFpEF will be enrolled to participate in this single center, event driven (positive nuclear amyloid scan also known as 99mTc-pyrophosphate SPECT scan) study. During the single study visit the following will be obta...

A Research Study to Look at How a New Medicine Called NNC6019-0001 Works and How Safe it is for People Who Have Heart Disease Due to Transthyretin (TTR) Amyloidosis
https://clinicaltrials.gov/ct2/show/NCT05442047

Oct 10th, 2022 - This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can reduce the symptoms of a heart disease due to TTR amyloidosis, such as heart failu...

see more →

News  431 results

Early Cardiac Amyloidosis Still Bad News Without Treatment
https://www.medpagetoday.com/cardiology/prevention/101789

Nov 16th, 2022 - For asymptomatic patients diagnosed with early-stage transthyretin amyloid cardiomyopathy (ATTR-CM), it can take just a few years to progress to clinical heart failure or other cardiovascular complications, according to a longitudinal cohort study...

Belantamab Mafodotin Fails to Meet PFS End Point in Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/belantamab-mafodotin-fails-to-meet-pfs-end-point-in-relapsed-refractory-multiple-myeloma

Nov 7th, 2022 - Belantamab mafodotin-blmf (Blenrep) did not generate a progression-free survival (PFS) benefit vs the combination of pomalidomide (Pomalyst) plus low-dose dexamethasone, failing to meet the primary end point of the phase 3 DREAMM-3 trial (NCT04162...

CRISPR Gene Editing Takes Next Step in TTR Amyloidosis
https://www.medscape.com/viewarticle/983609

Nov 5th, 2022 - Treatment with the investigational CRISPR-Cas9 gene-editing therapy, NTLA-2001, led to rapid responses in patients with transthyretin (TTR) amyloidosis with cardiomyopathy (ATTR-CM), interim phase 1 results show. Serum levels of the disease-causin...

FDA Grants Breakthrough Therapy Designation to Elranatamab for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-elranatamab-for-relapsed-refractory-multiple-myeloma

Nov 3rd, 2022 - The FDA has granted a breakthrough therapy designation to elranatamab (PF-06863135) for the treatment of patients with relapsed/refractory multiple myeloma, according to an announcement from Pfizer.1 The designation is based on 6-month follow-up ...

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL
https://www.onclive.com/view/first-patient-dosed-with-menin-inhibitor-bmf-219-in-covalent-101-trial-in-cll

Nov 1st, 2022 - The first patient in the chronic lymphocytic leukemia (CLL) cohort has been dosed in the phase 1 COVALENT-101 trial (NCT05153330), which is evaluating the first-in-class covalent menin inhibitor BMF-219, in patients with relapsed/refractory acute ...

see more →

Patient Education  34 results see all →